Soluble adhesion molecules levels in patients with Cushing's syndrome before and after cure

Journal of Endocrinological Investigation

Volumn 31, Issue 5, 2008, Pages 389-392

  Ermetici, F ^a   Malavazos, A E ^a   Corbetta, S ^a   Eller Vainicher, C ^b   Cannavo S ^c   Corsi, M M ^d   Ambrosi, Bruno ^a  

^a IRCCS POLICLINICO SAN DONATO   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

Cardiovascular risk; Cortisol; Cushing's syndrome; Endothelial function; ICAM I; VCAM I

Indexed keywords

CORTICOTROPIN; CORTISONE ACETATE; GLUCOSE; HYDROCORTISONE; INTERCELLULAR ADHESION MOLECULE 1; VASCULAR CELL ADHESION MOLECULE 1;

ACTH SECRETING ADENOMA; ADULT; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL FEATURE; COMORBIDITY; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; CUSHING SYNDROME; DIABETES MELLITUS; ENDOTHELIAL DYSFUNCTION; FEMALE; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE RELEASE; HYDROCORTISONE URINE LEVEL; HYPERCORTISOLISM; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; LIPID BLOOD LEVEL; MALE; OBESITY; PREVALENCE; REMISSION; TRANSSPHENOIDAL SURGERY;

EID: 48949116992     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03346381     Document Type: Article

References (16)

1. Schram MT, Stehouwer CDA. Endothelial dysfunction, cellular adhesion molecules and the metabolic syndrome. Horm Metab Res 2005, 37(Suppl 1): 49-55.
2. Leeuwenberg JF, Smeets EF, Neefjes JJ, et al. E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. Immunology 1992, 77: 543-9.
3. Schmidt AM, Hori O, Chen JX, et al. Advanced glycation end-products interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-I) in cultured human enclothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 1995, 96: 1395-403.
4. Mancini T, Kola B, Mantero F, Boscaro M, Arnaldi G. High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO/ISH guidelines. Clin Endocrinol (Cxf) 2004, 61: 768-77.
5. Faggiano A, Pivonello R, Spiezia S, et al. Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab 2003, 88: 2527-33.
6. Jurgilewicz DH, Rogowski F, Lebkowska U, Citko A, Jaroszewicz E, Parfieńczyk A. E-selectin, L-selectin, ICAM-I and IL-6 concentrations changes in the serum of patients with hyperthyroidism in the early period of radioiodine 1-131 therapy. Nucl Med Rev Cent East Eur 2002, 5: 39-42.
7. Diamanti-Kandarakis E, Paterakis T, Kandarakis HA. Indices of low-grade inflammation in polycystic ovary syndrome. Ann N Y Acad Sci 2006, 1092: 175-86.
8. Schäfer SC, Wallerath T, Closs EI, et al. Dexamethasone suppresses eNOS and CAT-I and induces oxidative stress in mouse resistance arterioles. Am J Physiol Heart Circ Physiol 2005, 288: H436-44.
9. Rogers KM, Bonar CA, Estrella JL, Yang S. Inhibitory effect of glucocorticoid on coronary artery enclothelial function. Am J Physiol Heart Circ Physiol 2002, 283: H1922-8.
10. Setola E, Losa M, Lanzi R, et al. Increased insulin-stimulated endothelin-1 release is a distinct vascular phenotype distinguishing Cushing's disease from metabolic syndrome. Clin Endocrinol (Oxf) 2007, 66: 586-92.
11. Arnaldi G, Angell A, Atkinson AB, et al. Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 2003, 88: 5593-02.
12. Colombo P, Dall'Asta C, Barbetta L, et al. Usefulness of the desmopressin test in the postoperative evaluation of patients with Cushing's disease. Eur J Endocrinol 2000, 143: 227-34.
13. Ito H, Chshima A, Inoue M, et al. Weight reduction decreases soluble cellular adhesion molecules in obese women. Clin Exp Pharmacol Physiol 2002, 29: 399-404.
14. Suzuki T, Shibata H, Ando T, et al. Risk factors associated with persistent postoperative hypertension in Cushing's syndrome. Endocr Res 2000, 26: 791-5.
15. Filipsson H, Monson JP, Koltowska-Häggström M, Mattsson A, Johannsson G. The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. J Clin Endocrinol Metab 2006, 91: 3954-61.
16. Swords FM, Carroll PV, Kisalu J, Wood PJ, Taylor NF, Monson JP. The effects of growth hormone deficiency and replacement on glucocorticoid exposure in hypopituitary patients on cortisone acetate and hydrocortisone replacement. Clin Endocrinol (Oxf) 2003, 59: 613-20.